The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis.
about
A patient-centred approach to biological treatment decision making for psoriasis: an expert consensusHealth-related quality of life worsens disproportionately to objective signs of psoriasis after withdrawal of adalimumab therapy.Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials.An evidence-based review of skin cancer rates on biologic therapies.Topical Turmeric Microemulgel in the Management of Plaque Psoriasis; A Clinical Evaluation.The efficacy of a health-related quality-of-life intervention during 48 weeks of biologic treatment of patients with moderate to severe psoriasis: study protocol for a multicenter randomized controlled trialHow psoriasis patients perceive, obtain, and use biologic agents: Survey from an academic medical center.Adalimumab in dermatologyEfficacy of Secukinumab for Moderate-to-Severe Head and Neck Psoriasis Over 52 Weeks: Pooled Analysis of Four Phase 3 Studies.Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives.Effect of Biologic Agents on Non-PASI Outcomes in Moderate-to-Severe Plaque Psoriasis: Systematic Review and Meta-Analyses.PASI90 response: the new standard in therapeutic efficacy for psoriasis.Anti-IL-17 Medications Used in the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review.A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis.Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab.Brodalumab for the treatment of psoriasis.Pharmacokinetic drug evaluation of brodalumab for the treatment of psoriasis.Comparative effectiveness of biologic therapies on improvements in quality of life in patients with psoriasis.The effect of etanercept on vascular endothelial growth factor production by cutaneous mesenchymal stem cells from patients with psoriasis.Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: an analysis of Japanese clinical trials of infliximab.Patient preferences for psoriasis treatments: impact of treatment experience.Life quality of Chinese patients with chronic urticaria as assessed by the dermatology life quality index.Cost effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United States.Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies.The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis.On clinical thresholds, clinical equivalents and indirect comparisons of biological treatments for moderate-to-severe psoriasis.Low-dose cyclosporin improves the health-related quality of life in Japanese psoriasis patients dissatisfied with topical corticosteroid monotherapy.The burden of psoriasis and barriers to satisfactory care: results from a Canadian patient survey.The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis.Long-term clinical safety and efficacy of brodalumab in the treatment of Japanese patients with moderate-to-severe plaque psoriasis.Acute Erythroderma in a Patient Receiving TNF-α-Blocking Therapy for Hidradenitis Suppurativa.
P2860
Q28082166-ADF91BC4-FB95-430C-908D-1B58E39C74AAQ33785083-AE3DC598-E5F8-48E3-A1DB-719F8B441357Q33844447-964B0EF4-7260-4F30-B432-8C93E9BDED25Q34107637-0F1B771C-86EE-4A97-9E79-50714802209EQ35897906-C2836618-FC4E-4E7F-B28C-BFDF96A3C77EQ36575333-C8E5514F-0E2F-4E1A-B220-C200F534ED3FQ36921945-05DAF584-BDF1-43F5-91DF-0BB1FD737DA6Q37142425-B2137B85-74C7-40BD-99FC-2444D2C0CB43Q37432244-B398E9FD-AA3A-4449-9D0C-C57182AF1A0AQ37857328-7286CB6F-65CD-4C00-8FA1-E433F429F538Q38064467-A71BCBB5-F8E5-43F0-BA67-6DA22B7634F5Q38265085-C402352F-49DA-4313-89B0-94297E1B7405Q38663614-7898DBD5-748E-49B7-956C-5CBF97866449Q38858335-919FB2C7-9F72-49D8-9E8F-8568D5DD2B75Q38925574-456FDE55-4CC4-410A-B5FA-92DCF297644EQ38975719-286F00D1-4A52-45D7-96D4-6486EC57D144Q39275772-81443CD4-79CC-447D-B307-AADDF7536999Q40261663-B4F5C8E2-84CD-44F9-9F9C-BEC3B976D288Q42008371-A6AC09A2-4A1A-46B4-AD9F-6C39940D6D73Q44456581-2395828C-29BB-4701-8C4D-CE3AEF39C900Q44849386-DEABA014-F86B-463E-B781-400ED3560CCEQ46503275-27416C42-1631-43E6-9C2C-9F42CB5B7407Q46945261-893B725C-8065-46C5-B2A6-E0908B833455Q47346793-22E21870-6B98-4455-83E6-2BA5DEAEFD29Q47644680-0FE4AA02-E162-4A18-8C11-C53C5BC13739Q48051795-0F98276A-6900-4DF2-A975-FEE65980EE6BQ48403095-3051987B-AF76-44FB-BEC1-A1C8719C49EDQ48952489-6B27D201-84D6-4FF6-9FE6-B7D1A8AA4034Q51350319-08659903-04B8-48AB-BA08-BCD8DA1A5099Q51435941-5D340FAB-A10E-45D3-8F4A-8D5F7CFEBB58Q52668444-A21E6D6F-80E0-49F5-9693-D30D46934810
P2860
The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The Dermatology Life Quality I ...... gical therapies for psoriasis.
@ast
The Dermatology Life Quality I ...... gical therapies for psoriasis.
@en
type
label
The Dermatology Life Quality I ...... gical therapies for psoriasis.
@ast
The Dermatology Life Quality I ...... gical therapies for psoriasis.
@en
prefLabel
The Dermatology Life Quality I ...... gical therapies for psoriasis.
@ast
The Dermatology Life Quality I ...... gical therapies for psoriasis.
@en
P2860
P1476
The Dermatology Life Quality I ...... gical therapies for psoriasis.
@en
P2093
R P Katugampola
P2860
P304
P356
10.1111/J.1365-2133.2007.07817.X
P407
P577
2007-03-28T00:00:00Z